{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:23:16Z","timestamp":1793197396737,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Limited information exists about survival outcomes after second primary cancers (SPCs) among breast cancer survivors. Studies suggest that mortality after certain SPCs may be higher than mortality after first primary cancers (FPCs) of the same type. A cohort study was conducted among 63,424 US women using the Surveillance, Epidemiology, and End Results 18 database (2000\u20132016) to compare mortality after a SPC among breast cancer survivors to mortality among women after a FPC using Cox proportional hazard regression. Propensity scores were used to match survivors with SPCs to women with FPCs 1:1 based on cancer type and prognostic factors. During a median follow-up of 42 months, 11,532 cancer deaths occurred after SPCs among survivors compared to 9305 deaths after FPCs. Cumulative cancer mortality was 44.7% for survivors with SPCs and 35.2% for women with FPCs. Survivors with SPCs had higher risk of cancer death (hazard ratio (HR): 1.27, 95% CI: 1.23\u20131.30) and death overall (HR: 1.18, 95% CI: 1.15\u20131.21) than women with FPCs. Increased risk of cancer death after SPCs compared to FPCs was observed for cancer in breast, lung, colon and\/or rectum, uterus, lymphoma, melanoma, thyroid, and leukemia. Estrogen receptor status and treatment of the prior breast cancer as well as time between prior breast cancer and SPC significantly modified the mortality difference between women with SPC and FPC. A more tailored approach to early detection and treatment could improve outcomes from second cancer in breast cancer survivors.<\/jats:p>","DOI":"10.1038\/s41523-022-00447-5","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T05:05:04Z","timestamp":1657775104000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Mortality after second malignancy in breast cancer survivors compared to a first primary cancer: a nationwide longitudinal cohort study"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9456-723X","authenticated-orcid":false,"given":"Zhengyi","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0582-8005","authenticated-orcid":false,"given":"Kala","family":"Visvanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"447_CR1","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3322\/caac.21565","volume":"69","author":"KD Miller","year":"2019","unstructured":"Miller, K. D. et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J. Clin. 69, 363\u2013385 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"447_CR2","unstructured":"Curtis R. E. et al. (eds). New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973\u20132000. (National Cancer Institute, NIH Publ. No. 05-5302. Bethesda, MD, 2006)."},{"key":"447_CR3","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s10549-011-1560-9","volume":"129","author":"HH Nsouli-Maktabi","year":"2011","unstructured":"Nsouli-Maktabi, H. H., Henson, D. E., Younes, N., Young, H. A. & Cleary, S. D. Second primary breast, endometrial, and ovarian cancers in Black and White breast cancer survivors over a 35-year time span: Effect of age. Breast Cancer Res. Treat. 129, 963\u2013969 (2011).","journal-title":"Breast Cancer Res. Treat."},{"key":"447_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ygyno.2014.10.029","volume":"136","author":"E Molina-Montes","year":"2015","unstructured":"Molina-Montes, E. et al. Risk of second cancers cancer after a first primary breast cancer: a systematic review and meta-analysis. Gynecol. Oncol. 136, 158\u2013171 (2015).","journal-title":"Gynecol. Oncol."},{"key":"447_CR5","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1200\/JCO.2007.11.9081","volume":"26","author":"M Schaapveld","year":"2008","unstructured":"Schaapveld, M. et al. Risk of new primary nonbreast cancers after breast cancer treatment: a dutch population-based study. J. Clin. Oncol. 26, 1239\u20131246 (2008).","journal-title":"J. Clin. Oncol."},{"key":"447_CR6","doi-asserted-by":"publisher","unstructured":"Mellemkj\u00e6r L. et al. Risk of second cancer among women with breast cancer. Int. J. Cancer. https:\/\/doi.org\/10.1002\/ijc.21651 (2006).","DOI":"10.1002\/ijc.21651"},{"key":"447_CR7","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1001\/jama.2020.23130","volume":"324","author":"H Sung","year":"2020","unstructured":"Sung, H., Hyun, N., Leach, C. R., Yabroff, K. R. & Jemal, A. Association of first primary cancer with risk of subsequent primary cancer among survivors of adult-onset cancers in the United States. JAMA - J. Am. Med. Assoc. 324, 2521\u20132535 (2020).","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"447_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10549-006-9446-y","volume":"105","author":"A Trentham-Dietz","year":"2007","unstructured":"Trentham-Dietz, A., Newcomb, P. A., Nichols, H. B. & Hampton, J. M. Breast cancer risk factors and second primary malignancies among women with breast cancer. Breast Cancer Res. Treat. 105, 195\u2013207 (2007).","journal-title":"Breast Cancer Res. Treat."},{"key":"447_CR9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/sj.bjc.6605435","volume":"102","author":"BA De Gonzalez","year":"2010","unstructured":"De Gonzalez, B. A. et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br. J. Cancer 102, 220\u2013226 (2010).","journal-title":"Br. J. Cancer"},{"key":"447_CR10","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/sj.bjc.6604241","volume":"98","author":"YM Kirova","year":"2008","unstructured":"Kirova, Y. M. et al. Second malignancies after breast cancer: The impact of different treatment modalities. Br. J. Cancer 98, 870\u2013874 (2008).","journal-title":"Br. J. Cancer"},{"key":"447_CR11","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA - J. Am. Med. Assoc. 317, 2402\u20132416 (2017).","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"447_CR12","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1200\/JCO.2013.54.6119","volume":"33","author":"AC Wolff","year":"2015","unstructured":"Wolff, A. C. et al. Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. J. Clin. Oncol. 33, 340\u2013348 (2015).","journal-title":"J. Clin. Oncol."},{"key":"447_CR13","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2006.10.5056","volume":"25","author":"M Hartman","year":"2007","unstructured":"Hartman, M. et al. Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J. Clin. Oncol. 25, 4210\u20134216 (2007).","journal-title":"J. Clin. Oncol."},{"key":"447_CR14","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/ijc.31543","volume":"143","author":"H Zhou","year":"2018","unstructured":"Zhou, H. et al. Impact of prior cancer history on the overall survival of patients newly diagnosed with cancer: a pan-cancer analysis of the SEER database. Int J. Cancer 143, 1569\u20131577 (2018).","journal-title":"Int J. Cancer"},{"key":"447_CR15","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1001\/jamaoncol.2017.0465","volume":"3","author":"THM Keegan","year":"2017","unstructured":"Keegan, T. H. M., Bleyer, A., Rosenberg, A. S., Li, Q. & Goldfarb, M. Second primary malignant neoplasms and survival in adolescent and young adult cancer survivors. JAMA Oncol. 3, 1554\u20131557 (2017).","journal-title":"JAMA Oncol."},{"key":"447_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10549-018-4846-3","volume":"171","author":"R Langballe","year":"2018","unstructured":"Langballe, R. et al. Mortality after contralateral breast cancer in Denmark. Breast Cancer Res. Treat. 171, 489\u2013499 (2018).","journal-title":"Breast Cancer Res. Treat."},{"key":"447_CR17","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10549-011-1618-8","volume":"130","author":"V Vichapat","year":"2011","unstructured":"Vichapat, V. et al. Prognosis of metachronous contralateral breast cancer: Importance of stage, age and interval time between the two diagnoses. Breast Cancer Res. Treat. 130, 609\u2013618 (2011).","journal-title":"Breast Cancer Res. Treat."},{"key":"447_CR18","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s10549-013-2588-9","volume":"139","author":"A Font-Gonzalez","year":"2013","unstructured":"Font-Gonzalez, A. et al. Inferior survival for young patients with contralateral compared to unilateral breast cancer: A nationwide population-based study in the Netherlands. Breast Cancer Res. Treat. 139, 811\u2013819 (2013).","journal-title":"Breast Cancer Res. Treat"},{"key":"447_CR19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.2325\/jbcs.12.196","volume":"12","author":"H Takahashi","year":"2005","unstructured":"Takahashi, H., Watanabe, K., Takahashi, M., Taguchi, K., Sasaki, F. & Todo, S. The impact of bilateral breast cancer on the prognosis of breast cancer: A comparative study with unilateral breast cancer. Breast Cancer 12, 196\u2013202 (2005).","journal-title":"Breast Cancer"},{"key":"447_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10549-006-9455-x","volume":"105","author":"HM Verkooijen","year":"2007","unstructured":"Verkooijen, H. M. et al. Survival after bilateral breast cancer: Results from a population-based study. Breast Cancer Res. Treat. 105, 347\u2013357 (2007).","journal-title":"Breast Cancer Res. Treat."},{"key":"447_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10549-010-1057-y","volume":"126","author":"EAH Kheirelseid","year":"2011","unstructured":"Kheirelseid, E. A. H. et al. Bilateral breast cancer: Analysis of incidence, outcome, survival and disease characteristics. Breast Cancer Res. Treat. 126, 131\u2013140 (2011).","journal-title":"Breast Cancer Res. Treat"},{"key":"447_CR22","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10549-015-3538-5","volume":"153","author":"JJ Jobsen","year":"2015","unstructured":"Jobsen, J. J., van der Palen,J., Ong, F., Riemersma, S. & Struikmans, H. Bilateral breast cancer, synchronous and metachronous; differences and outcome. Breast Cancer Res. Treat. 153, 277\u2013283 (2015).","journal-title":"Breast Cancer Res. Treat."},{"key":"447_CR23","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","volume":"33","author":"LSG \u00d8stg\u00e5rd","year":"2015","unstructured":"\u00d8stg\u00e5rd, L. S. G. et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J. Clin. Oncol. 33, 3641\u20133649 (2015).","journal-title":"J. Clin. Oncol."},{"key":"447_CR24","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","volume":"52","author":"KL Bolton","year":"2020","unstructured":"Bolton, K. L. et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat. Genet. 52, 1219\u20131226 (2020).","journal-title":"Nat. Genet."},{"key":"447_CR25","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal, S. et al. Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes. N. Engl. J. Med. 371, 2488\u20132498 (2014).","journal-title":"N. Engl. J. Med."},{"key":"447_CR26","doi-asserted-by":"publisher","unstructured":"Jones M. E. et al. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries. Breast Cancer Res. 14, https:\/\/doi.org\/10.1186\/bcr3206 (2012).","DOI":"10.1186\/bcr3206"},{"key":"447_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10549-007-9823-1","volume":"112","author":"WE Hoogendoorn","year":"2008","unstructured":"Hoogendoorn, W. E. et al. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. Breast Cancer Res. Treat. 112, 99\u2013108 (2008).","journal-title":"Breast Cancer Res. Treat."},{"key":"447_CR28","doi-asserted-by":"crossref","unstructured":"Deng, Z., Jones, M.R., Visvanathan, K. Comparison of tumor profiles of second cancers among breast cancer survivors to first cancers in the SEER registries: a nationwide study [abstract]. Proc Am Assoc Cancer Res Annu Meet 2021; 2021 Apr 10\u201315 May 17\u201321 Philadelphia AACR; Cancer Res 2021;81(13_Suppl) Abstract nr 896.","DOI":"10.1158\/1538-7445.AM2021-896"},{"key":"447_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamanetworkopen.2021.3520","volume":"4","author":"F Petrelli","year":"2021","unstructured":"Petrelli, F. et al. Association of obesity with survival outcomes in patients with cancer: a systematic review and meta-analysis. JAMA Netw. Open 4, 1\u201330 (2021).","journal-title":"JAMA Netw. Open"},{"key":"447_CR30","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1111\/cas.14175","volume":"110","author":"Z Fan","year":"2019","unstructured":"Fan, Z. et al. Germline mutation in DNA-repair genes is associated with poor survival in BRCA1\/2-negative breast cancer patients. Cancer Sci. 110, 3368\u20133374 (2019).","journal-title":"Cancer Sci."},{"key":"447_CR31","doi-asserted-by":"crossref","unstructured":"Laccetti, A. L., Pruitt, S. L., Xuan, L., Halm, E. A. & Gerber, D. E. Effect of prior cancer on outcomes in advanced lung cancer: Implications for clinical trial eligibility and accrual. J Natl Cancer Inst. 107, 1\u20139 (2015).","DOI":"10.1093\/jnci\/djv002"},{"key":"447_CR32","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1200\/JCO.2014.58.3088","volume":"33","author":"JL Westmaas","year":"2015","unstructured":"Westmaas, J. L., Newton, C. C., Stevens, V. L., Flanders, W. D, Gapstur, S. M. & Jacobs, E. J. Does a recent cancer diagnosis predict smoking cessation? An analysis from a large prospective US cohort. J. Clin. Oncol. 33, 1647\u20131652 (2015).","journal-title":"J. Clin. Oncol."},{"key":"447_CR33","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3109\/07357901003630959","volume":"28","author":"JL Lund","year":"2010","unstructured":"Lund, J. L., Harlan, L. C., Yabroff, K. R. & Warren, J. L. Should cause of death from the death certificate be used to examine cancer-specific survival a study of patients with distant stage disease. Cancer Investig. 28, 758\u2013764 (2010).","journal-title":"Cancer Investig."},{"key":"447_CR34","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Registries Custom Data (with additional treatment fields), Nov 2018 Sub (1975\u20132016 varying) - Linked To County Attributes - Total U.S., 1969. National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, based on the November 2018 submission."},{"key":"447_CR35","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1002\/cncr.32356","volume":"125","author":"AL Brown","year":"2019","unstructured":"Brown, A. L. et al. Survival disparities for second primary malignancies diagnosed among childhood: A population-based assessment. Cancer 125, 3623\u20133630 (2019).","journal-title":"Cancer"},{"key":"447_CR36","unstructured":"SEER. Site Recode ICD-O-3\/WHO 2008 Definition. https:\/\/seer.cancer.gov\/siterecode\/icdo3_dwhoheme\/index.html."},{"key":"447_CR37","unstructured":"SEER. U.S. Mortality Data, 1969\u20132018. https:\/\/seer.cancer.gov\/mortality\/."},{"key":"447_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/09-STS313","volume":"25","author":"EA Stuart","year":"2010","unstructured":"Stuart, E. A. Matching Methods for Causal Inference: A Review and a Look Forward. Statist. Sci. 25, 1\u201321 (2010).","journal-title":"Statist. Sci."}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-022-00447-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-022-00447-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-022-00447-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:37:18Z","timestamp":1669297038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-022-00447-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["447"],"URL":"https:\/\/doi.org\/10.1038\/s41523-022-00447-5","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]},"assertion":[{"value":"9 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}